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ABSTRACT
Objectives: Our retrospective study aimed to evaluate the rate and the appropriate use of antenatal corticosteroid therapy, 
and their effect on the incidence and treatment of respiratory distress syndrome (RDS) and its complications.
Material and methods: A retrospective analysis of clinical practice in Poland was performed using standard investigating 
tools: a questionnaire on the frequency of using antennal corticosteroids in the selected centers, as well as neonatal data. 
A total of 987 newborns at ≤ 32 weeks of gestation, treated in 54 centers (including 42 tertiary and 12 secondary referral 
centers) over a period of 6 months in 2013, were deemed eligible. The study group consisted of 749 newborns whose 
mothers received antenatal steroids. The non-steroid group included 238 newborns.
Results: Antenatal corticosteroids were administered to 75.89% of the neonates from the study group, with 79% and 
21% receiving one and two courses, respectively. Children whose mothers received prenatal steroids presented with less 
extensive radiographic changes typical of RDS, and less often required surfactant therapy (70% vs. 78%; p = 0.0143). In the 
group of children undergoing antenatal steroid therapy, the percentage of BPD was lower (13.27% vs. 18.63%) (p = 0.0881). 
The mortality rates were 20.91% and 10.81% in controls and the study group, respectively (p = 0.0001).
Conclusions: 
1. The percentage of antenatal steroid use in secondary and tertiary referral centers in Poland is unsatisfactorily low (76%).
2. Antenatal corticosteroids demonstrated high efficacy in decreasing severe forms of RDS, less need for surfactant 
therapy, and reduced BPD and mortality rates.
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INTRODUCTION
Advances in the treatment of preterm neonates have 
been achieved mainly due to the use of endogenous sur-
factant and antenatal corticosteroids. Both of these peri-
natal therapies have significantly decreased the mortality 
rates among children with low and extremely low birth 
weight, as well as the number of complications, especially 
bronchopulmonary dysplasia [1]. The beneficial effect of 
glucocorticosteroids was discovered over five decades ago. 
Forty years ago, Liggins, in his study on preterm lambs, 
observed higher survival rates and less lung damage after 
administration of these drugs [2]. Experimental studies show 
a beneficial effect, demonstrated as increased amount of 
surfactant and respiratory epithelium, resulting in lower 
permeability and lower leakage of proteins into the alveolar 
lumens. Glucocorticosteroids accelerate the absorption of 
lung liquid and maturation of lung interstitium, which in 
turn has a favorable effect on the total lung capacity [3, 4]. 
Data published in 2000 in Pediatrics, which summed up 
20 years of antenatal corticosteroid use, demonstrated their 
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safety by reporting no influence on the process of puberty 
and growth in 12-year-olds who were born preterm and 
received ACS [5].
OBJECTIVES
The aim of our study was to evaluate the frequency 
and the protocol for the use of antenatal corticosteroids 
in 54 neonatal centers in Poland, including 42 tertiary and 
12 secondary referral centers, as well as their effect on the in-
cidence and treatment of respiratory distress syndrome and 
its complications - bronchopulmonary dysplasia and death. 
MATERIAL AND METHODS
A retrospective analysis of clinical practice in Poland was 
performed using standard investigating tools: a question-
naire on the frequency of using antennal corticosteroids 
in the selected centers, as well as data on the incidence of 
RDS, BPD, and deaths. Data of 987 newborns at the gesta-
tional age of ≤ 32 weeks, treated in 54 centers (including 
42 tertiary and 12 secondary referral centers) over a period 
of 6 months in 2013 (between January 1, 2013 and June 30, 
2013), were deemed eligible. The study group consisted of 
749 newborns whose mothers received antenatal steroids, 
whereas 238 of the 987 newborns whose mothers did not 
receive steroids constituted the control group.
The following parameters were analyzed: the rate of 
corticosteroid therapy use, severity of RDS, frequency and 
method of surfactant administration, type of drug, time 
interval between last dosage and the use of FiO2 during 
resuscitation in the delivery room, length of invasive ventila-
tion, incidence of BPD (defined as the need to use oxygen 
therapy at the age of 36 weeks of postconceptional age), as 
well as the mortality rate. Characteristics of the newborns 
are presented in Figure 1. 
The results of the descriptive analysis of the qualitative 
data were presented as percentages:
i = m/n * 100%,
with: i — coefficient (percentage),
m — number of subjects with a given feature,
n — sample size 
Each coefficient calculated in the abovementioned way 
was given a confidence interval. 
Quantitative variables were described using measures 
of central tendency — mean, median (Me) and modal (Mo) 
values, as well as measures of dispersion and differentiation 
— standard error (SE), standard deviation (SD), confidence 
interval (CI) for the mean, and minimum and maximum 
value of a variable. The CI was established at 95%. 
RESULTS
There were no statistical significant differences in birth 
weight (mean: 1200 g), gestational age (mean: 28 weeks). 
However, in the study group there were significantly fewer 
outborn babies (p < 0.0001), as well as newborns born with 
Apgar score < 6 at 1 min of life (Table 1). Antenatal corti-
costeroids were administered to 75.89% of the neonates 
from the study group, with 79% and 21% receiving one 
and two courses, respectively. The lowest percentage of 
corticosteroid therapy was noted in mothers of the most 
premature infants (23–24 weeks of gestational age) and 
of neonates at 32 weeks of gestational age (55% and 74%, 
respectively). Table  2 shows the percentage of antenatal 
steroid administration in different weeks of pregnancy. The 
time interval between steroid administration and delivery 
varied, ranging from 0.5 hours to 60 days. Betamethasone 
and dexamethasone were given to the same number of 
subjects. We received data on the necessity of intubation in 
the delivery room about 949 of the 987 newborns. Data were 
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analyzed in four groups, depending on the time elapsed 
since the last dose of steroids until birth: 
1. the last dose was given between 24 h (= 1 day) to 
14 days before delivery; 
2. no steroids were administered prenatally; 
3. the last dose was given at a different time 
than 1–14 days before delivery; 
4. steroids were given but time of the administration 
is unknown (Table 3).
In 719 newborns maximal FiO2 at the Delivery Room (max-
FiO2) was noted. Mean values of maxFiO2 were 0.59 and 0.49 in 
the control and the study group, respectively (p = 0.0005) 
(Figure 1). We obtained data on mechanical ventilation 
about all 987 newborns. Mean time of invasive ventilation 
was 7.8 days and 5.7 days, respectively in the non-steroid 
and steroid groups (p < 0.0001) (Figure 1). Children whose 
mothers received prenatal steroids presented less extensive 
radiographic changes typical of RDS and less often required 
surfactant therapy (70% vs. 78%; p = 0.0143) (Table 1, Fig-
ure 2). As many as 93.1% of the newborns (gestational age 
of < 28 weeks) whose mothers did not receive antenatal 
corticosteroids required surfactant therapy. The incidence of 
BPD was analyzed in 726 newborns. In the group of children 
undergoing antenatal steroid therapy, the percentage of BPD 
was lower (13.27% vs. 18.63%) p = 0.0881 RR = 0.7124 (Fig-
ure 2). The mortality rate was 20.91% in the control group and 
10.81% in the study group (p = 0.00001) RR = 0.5172 (Figure 2). 
These data are statistically significant.
In summary, in children who received prenatal cortico-
steroids, as compared to infants not exposed to corticoste-
roids, the following were observed: 
1. lower risk of death within a period of 36 weeks of 
postconceptional age (10.8% vs. 20.9% in control 
p = 0.0001; RR = 0.5172 [95% CI: 0.3695–0.7239]); 
2. lower risk of the need for surfactant treatment (re-
spectively, 69.9% vs. 78.1% in control p = 0.0143; 
RR = 0.8952 [95% CI: 0.8247–0.9716]);
Table 1. Newborns characteristics
Characteristics Antenatal corticosteroids(n = 749)
Controls
(n = 238) P value
Birth weight, g, mean (5th, 95th percentile) 1216 (600, 1980) 1209 (520, 2021) 0,6465
GA, wk, mean (5th, 95th percentile) 28.7 (24, 32) 28.3 (23, 32) 0.3191
Sex, male, n [%] 390 (52.0) 124 (52, 1) 0.9933
Outborn, n [%] 38 (5.0) 54 (22, 7) < 0.0001
Apgar at 1 min, median (IQR) 6 (4–7) 5 (2–6) < 0.0001
Apgar at 5 min, median (IQR) 7 (6–8) 7 (6–8) 0.0084
Maximal FiO2 at DR, mean (5
th, 95th percentile) 0.49 (0.25, 1) 0.59 (0.29, 1) 0.0005
Surfactant treatment, n [%] 524 (69.9) 186 (78.1) 0.0143
Table 2. Antenatal steroids in different weeks of pregnancy in study 
and control group
Gestational age
[weeks]
Steroids group
[%]
No steroids group
[%]
22 33.33 66.67
23 55.00 45.00
24 63.46 36.54
25 82.00 18.00
26 78.35 21.65
27 74.44 25.56
28 80.18 19.82
29 81.25 18.75
30 74.50 25.50
31 78.03 21.97
32 73.68 26.32
Table 3. Intubation at delivery room and antenatal steroids 
INTUBATION Steroids1–14 days before delivery No steroids
Steroids 
> 14 days before delivery
Steroids
Unknown time  before delivery Total number
NO
N-255 N-121 N-145 N-18 542
59.72% 51.95% 60.41% 40.91
YES
172 112 97 26 407
40.28% 48.07% 39.59% 59.09%
Total numer 427 233 245 44 949
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3. lower oxygen demand — lower max. value 
FiO2 during stabilization in the delivery room (me-
dian FiO2 of 0.4 and 0.5, respectively, p = 0.0005, the 
U Mann-Whitney test);
4. less invasive ventilation time (average 5.7 ± 1.4 days 
and 7.9 ± 12.7 days, respectively; p < 0.0001); 
5. a trend for less frequent need for intubation imme-
diately in the delivery room in the group of children 
whose mothers received the last dose of steroids 
in the period of > 24 h and < 14 days before giving 
birth, as compared to children who did not receive 
steroids (40.3% vs. 48.0%, p = 0.0535). A statistically 
significant difference was observed between the 
use of prenatal steroids depending on gestational 
age (p = 0.00836); the least frequent use at 22 and 
23 weeks (33.33% and 55% of the children).
DISCUSSION
Despite over 19 000 articles on antenatal corticosteroid 
therapy to be found in PubMed, as well as the fact that 
antenatal steroids and surfactant have been used for forty 
years, Poland lacks satisfactory amount of data on mutual 
correlations of these drugs. Our findings regarding almost 
987 newborns aimed to bridge that gap. The National Insti-
tutes of Health (NIH), the American College of Obstetricians 
and Gynecologists (ACOG), and other associations also 
Polish Gynecological Society have been recommending 
administration of antenatal corticosteroids before 34 weeks 
of gestation in women at risk for preterm birth since the 
end of the twentieth century [6, 7]. The latest reports have 
recommended steroid use until 36 weeks of gestation, as 
such management decreases morbidity and mortality rates 
of most preterm neonates Detailed reports on the rules 
governing ACS use were included in four recommendations 
of the Royal College of Obstetricians and Gynecologists, 
published in 1996, 1999, 2004 and 2010 [8–11]. In 2008, the 
guidelines of the World Association of Perinatal Medicine 
Prematurity Working Group on the use of ACS to stimulate 
fetal lung maturity were published in the Journal of Peri-
natal Medicine [12]. Numerous other reports summarize 
large amount of data documenting the effect of these 
drugs on the stimulation of type II pneumocytes and release 
of surfactant, and the efficacy and necessity of their use, 
which surpasses the possible adverse effects [13, 14]. A me-
ta-analysis of data collected by Crowley, from 15 projects 
published over a period of 22 years (1972–1994), revealed 
a 50% drop in the RDS rates (OR 0.35; 95% CI: 026–0.46), as 
well as lower rates of intraventricular hemorrhage — IVH 
(OR 0.38; 95% CI: 0.23–0.94) and necrotizing enterocolitis 
— NEC (OR 0.32; 95% CI: 0.16–0.64), but did not show any 
correlation between corticosteroid use and the incidence 
of BPD [15]. Similar findings were reported by Spencer and 
Neales, who observed decreased rates of IVH and NEC, as 
well as a group of neonatologists from Brazil, who studied 
1051 neonates born < 34 weeks of gestation [16, 17]. Our 
study was limited only to the evaluation of clinical severity 
of RDS, as well as intubation in the delivery room, mechani-
cal ventilation BPD rates of death. We demonstrated lower 
RDS rates, and a less frequent need for surfactant use in 
the study group as compared to children whose mothers 
did not receive steroid therapy (70% vs. 78%) (Figure 2). 
Neonates who received corticosteroids in utero notably less 
often required surfactant therapy or developed BPD. The 
75.89% rate of administration of antenatal steroids noted 
in our study remains too low. The percentage of using ACS 
in other European countries is much higher (95%), whereas 
in Australia it reached the level of 97% already in the 90s of 
the previous century [18]. However, an analysis of 9 Scottish 
centers detected a 45% ACS use [19]. Currently, 210 cent-
ers in Great Britain declare a 98% rate of ACS use [20]. The 
low rate of administering ACS to Polish neonates at the 
gestational age of 22–23 weeks, i.e. (33.3% and 55%), when 
Outcome Steroids Control 
 (n/N) (n/N) RR (95% Cl)
Favours steroids Favours controls
0.0 0.5 1.0 1.5
Surfactant therapy 524/749 186/238 0.8952 (0.8247–0.9716)
Intubation at DR 295/716 112/233 0.8571 (0.7307–1.0050)
BPD in survivors 75/565 30/161 0.7124 (0.4845–1.0480)
Death 73/675 45/220 0.5172 (0.3695–0.7239)
Figure 2. Relative Risk of incidence of intubation at delivery room, surfactant therapy, BPD and death in study and control group
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neonatologists often choose not to intervene and limit their 
activity to palliative care, may be interpreted in various 
ways. On one hand, it indicates that obstetricians are con-
vinced, sometimes mistakenly, of low chances to maintain 
pregnancy in the face of such early threat of premature 
labor, and on the other hand, of lack of a favorable effect of 
ACS on immature lungs. The rationale behind such opinions 
is the fact that glucocorticoid activity is conditioned by 
the number of receptors for corticosteroids, physiological 
activity of hormones, and genetic factors [3]. Typically, one 
course of steroids is administered in daily obstetric practice, 
whereas the second course continues to remain controver-
sial if preterm labor did not occur in a few weeks after the 
first course. In our study, one course of ACS — 2 × 12 mg at 
24 h intervals — was also the dominant management (79% 
and 21%). Already by the end of the previous century, most 
American and European obstetrician used more than one 
course of ACS. However, despite reports on higher efficacy 
of repeated ACS courses on the parameters of lung func-
tion, especially in neonates with significant immaturity, 
such management was largely abandoned due to growth 
restriction, decreased brain volume, and unclear long-term 
effects [21]. After numerous experimental and randomized 
studies, in 2005 the National Institute of Health of the U.S. 
Health Department published a statement declaring the 
lack of scientific rationale for validity and efficacy of re-
peated courses of steroid therapy [22]. These recommen-
dations were confirmed, among others, by experimental 
studies on monkeys, sheep, rabbits, and mice, indicating 
delayed brain development and growth retardation, as well 
as increased rates of NEC and sepsis [23]. In our study, the 
time elapsed between the last dose of corticosteroids and 
the delivery varied greatly. As many as 25% of the subjects 
gave birth < 24 h since the administration of the drug. The 
actual efficacy is perhaps extremely low, but most recom-
mendations claim a beneficial effect of the therapy even in 
such cases . Already Liggins and Howie, in their practically 
‘historical’ publication from 1972, proved the highest ef- 
ficacy of steroid therapy after 24 h of life until up to 10 days 
since its commencement [2]. Our data indicate an equal 
frequency of betamethasone and dexamethasone use but, 
obviously, their dosing schemes differ, and Polish hospitals 
do not always comply with them. Betamethasone is given as 
two doses of 12 mg, 24 h apart, and dexamethasone as four 
doses of 6 mg, 12 h apart [24]. Both drugs are recommended 
by experts worldwide. Although the only structural differ-
ence between both drugs is one methyl group, and despite 
having different transfer across the placenta, in cord blood 
they both reach approximately 30% of drug activity in ma-
ternal blood and both have immunosuppressant activity, as 
well as minimal activity of mineralocorticoids. Nevertheless, 
Job and Soll emphasize a higher efficacy of betametha-
sone in reducing mortality rates among neonates, possibly 
caused by its longer half-life and lower concentrations in 
blood serum [25]. Other studies demonstrate a decreased 
risk for leukomalacia after betamethasone treatment [26]. 
CONCLUSIONS 
1. The percentage of glucocorticosteroids used in sec-
ondary and tertiary referral centers in Poland is unsat-
isfactorily low (76%), and differs from other European, 
American, or Australian centers. 
2. The protocols for the use of ACS and the doses are con-
sistent with European and global recommendations. 
3. Based on a large sample size of 987 neonates at the 
gestational age of ≤ 32 weeks from 54 Polish neonatal 
centers, we demonstrated high efficacy of antenatal 
corticosteroid use in decreasing severe forms of RDS, 
lower necessity of surfactant therapy, and reduced BPD 
and mortality rates.
Source of financing
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